United States Navy
Also known as: CUBRC, MTEC, and US Navy | Enteric Disease Department, Naval Medical Research Center | Enteric Diseases Department Naval Medical Research Center | Enteric Diseases Department, Naval Medical Research Center | National Naval Medical Center | National Naval Medical Center, Bethesda | Naval Aeromedical Research Unit, Dayton | Naval Health Research Center | Naval Health Research Center - San Diego | Naval Hospital Camp Lejeune | Naval Hospital Camp Pendleton | NavalMCSD Pain Center | Naval Medical Center Camp Lejeune | Naval Medical Center San Diego Department of Orthopadic Surgery | Naval Medical Research Center | Naval Medical Research Center, Asia (NMRC-A) | Naval Medical Research Center (NMRC) | Naval Medical Research Unit- 3 | Naval Medical Research Unit- 6 | Naval Medical Research Unit - Dayton | Naval Medical Research Unit No 6 | Naval Officer, Naval Medical Center - Portsmouth | Navy Advanced Medical Development (NAMD) Command | Navy Bureau of Medicine and Surgery | Navy General Hosiptal | Navy Medical Center San Diego | Navy Medical Center, San Diego | Navy Medical Research Center | Navy Warfighter Refractive Surgery San Diego | NMCSD | NMRTC Bethesda | Office of Naval Research (ONR) | United States Naval Medical Center, Portsmouth | United States Naval Medical Center, San Diego | United States Naval Medical Center, San Diego,CA | United States Navy | US Military Vaccine Program, NMRC PI, Naval Officer | US Naval Medical Research Unit | U.S. Naval Medical Research Unit No. 3 | US Navy | U.S. Navy Bureau of Medicine | Virology and Rickettsial Diseases Department, Naval Medical Research Center
Highest phase reached
Phase 4
First clinical trial
Aug 1, 1998Last known activity
Dec 1, 2024
Timeline
1770s
- Oct 13, 1775
United States Navy— Founded
Drugs by trial phase (135 distinct, 110 trials)
Phase 4 (18 own, 0 via acquisition)
Phase 3 (29 own, 0 via acquisition)
Phase 2 (26 own, 0 via acquisition)
- nitroglycerin
- oxytocin
- mirabegron
- bone autograft
- carbon dioxide
- ibuprofen
- hydroxychloroquine
- imm-124e
- platelet-rich plasma
- pravibismane
- acetaminophen
- pantoprazole
- adenovirus-vectored malaria vaccines encoding plasmodium falciparum circumsporozoite protein and apical membrane antigen 1
- anti-cs17 bovine igg
- anti-csbd bovine igg
- +11 more
Phase 1 (35 own, 0 via acquisition)
Indications
Studied for
- Altitude Sickness
- Biliary Tract Diseases
- Calculi
- Campylobacter Infections
- Carcinoma in Situ
- Cervical Intraepithelial Neoplasia
- Cholecystolithiasis
- Cholelithiasis
- Condylomata Acuminata
- Corneal Opacity
- Dengue
- Depression
- Depressive Disorder
- Diarrhea
- Disease
- Dry Eye Syndromes
- Dysentery
- Dysentery, Bacillary
- Emergencies
- Escherichia coli Infections
- Fibrosis
- Gallstones
- Headache
- Hemorrhage
- Hernia
- Hernia, Inguinal
- Hyperplasia
- Infections
- Influenza, Human
- Keratoconjunctivitis Sicca
- Kidney Calculi
- Malaria
- Malaria, Falciparum
- Migraine Disorders
- Motion Sickness
- Nausea
- Neoplasms
- Nephrolithiasis
- Osteoarthritis
- Osteoarthritis, Hip
- Osteoarthritis, Knee
- Papilloma
- Peripheral Nervous System Diseases
- Phantom Limb
- Pneumonia
- Post-Dural Puncture Headache
- Postpartum Hemorrhage
- Prostatic Neoplasms
- Psychomotor Agitation
- Radiculopathy
- Respiration Disorders
- Respiratory Tract Diseases
- Shoulder Injuries
- Shoulder Pain
- Skin Neoplasms
- Suicide
- Tendinopathy
- Ureteral Calculi
- Ureterolithiasis
- Warts
- Wounds and Injuries
Recent trials (50)
- NCT06989866OfficialPhase 3Dec 1, 2024
- NCT06989866Lead sponsorPhase 3Dec 1, 2024
- NCT06252662Lead sponsorPhase 4Sep 30, 2024
- NCT06252662Sponsor investigatorPhase 4Sep 30, 2024
- NCT06273462Lead sponsorPhase 2Aug 5, 2024
- NCT05959616CollaboratorPhase 1Mar 1, 2024
- NCT06122870CollaboratorPhase 1Dec 4, 2023
- NCT05990387CollaboratorPhase 1/Phase 2Jul 19, 2023
- NCT05933525CollaboratorPhase 2May 29, 2023
- NCT05883397CollaboratorN/AMay 25, 2023
- NCT06054269OfficialPhase 3Nov 4, 2022
- NCT06054269Overall official - principal investigatorPhase 3Nov 4, 2022
- NCT06054269CollaboratorPhase 3Nov 4, 2022
- NCT05598723Study directorPhase 3Nov 1, 2022
- NCT05598723Overall official - principal investigatorPhase 3Nov 1, 2022
Details
- Founded
- Arlington, VA, US Oct 13, 1775
- Last known activity
- Dec 1, 2024